Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on markers of VTE and CVD risk, in PCOS. In a double-blind, placebo-controlled, randomized trial, 72 overweight and/or insulin-resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference in change (baseline to follow-up) in plasminogen activator inhibitor-1 levels and in thrombin generation test parameters: endogenous thrombin potential, peak thrombin concentration, lag time and time to peak. Mean weight loss was 5.2 kg (95% CI 3.0–7.5 kg, P < 0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group, peak thrombin concentration decreased by 16.71 nmol/L (95% CI 2.32–31.11, P < 0.05) and lag time and time to peak increased by 0.13 min (95% CI 0.01–0.25, P < 0.05) and 0.38 min (95% CI 0.09–0.68, P < 0.05), respectively, but there were no between-group differences. There was a trend toward 12% (95% CI 0–23, P = 0.05) decreased plasminogen activator inhibitor-1 in the liraglutide group, and there was a trend toward 16% (95% CI −4 to 32, P = 0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend toward improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point toward beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies compared the liraglutide 1.8 mg/day vs. placebo for 26 weeks and demonstrated a greater efficacy in terms of reduction of body weight and waist circumference (WC) in the liraglutide group [54–56].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Thrombin generation and fibrin clot structure
Wolberg, A. S. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.11.001 · Cited by 747
Thrombin generation, a function test of the haemostaticthrombotic system
Al Dieri, R., De Smedt, E., Béguin, S., & Hemker, H. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-07-0408 · Cited by 467
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Diamanti-Kandarakis, E., Paterakis, T., Alexandraki, K., Piperi, C., Aessopos, A., Katsikis, I., Katsilambros, N., Kreatsas, G., & Panidis, D. (2006) · Human Reproduction · doi:10.1093/humrep/del003 · Cited by 258
Velazquez, E. M., Mendoza, S. G., Wang, P., & Glueck, C. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90066-4 · Cited by 249
Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome
Morin-Papunen, L., Rautio, K., Ruokonen, A., Hedberg, P., Puukka, M., & Tapanainen, J. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021688 · Cited by 245
Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome
Toulis, K. A., Goulis, D. G., Mintziori, G., Kintiraki, E., Eukarpidis, E., Mouratoglou, S.-A., Pavlaki, A., Stergianos, S., Poulasouchidou, M., Tzellos, T. G., et al. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmr025 · Cited by 228
Daan, N. M. P., Louwers, Y. V., Koster, M. P. H., Eijkemans, M. J. C., de Rijke, Y. B., Lentjes, E. W. G., Fauser, B. C. J. M., & Laven, J. S. E. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.08.001 · Cited by 217
Liu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187
Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.
Zhao, L., Zhu, Z., Lou, H., Zhu, G., Huang, W., Zhang, S., & Liu, F. (2016) · Oncotarget · doi:10.18632/oncotarget.9553 · Cited by 174
Agarwal, N., Rice, S. P. L., Bolusani, H., Luzio, S. D., Dunseath, G., Ludgate, M., & Rees, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1985 · Cited by 162
Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis
Sonneveld, M., de Maat, M. P. M., & Leebeek, F. W. G. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.04.003 · Cited by 158
Adipokines at the crossroad between obesity and cardiovascular disease
Morel, S., Kwak, B., Rohner-Jeanrenaud, F., Steffens, S., & Molica, F. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0513 · Cited by 146
Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Cameron-Vendrig, A., Reheman, A., Siraj, M. A., Xu, X. R., Wang, Y., Lei, X., Afroze, T., Shikatani, E., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 137
Prediction of Recurrent Venous Thromboembolism by Endogenous Thrombin Potential and D-Dimer
Eichinger, S., Hron, G., Kollars, M., & Kyrle, P. A. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.112243 · Cited by 134
Bird, S. T., Hartzema, A. G., Brophy, J. M., Etminan, M., & Delaney, J. A. C. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.120677 · Cited by 126
Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study
Tofler, G. H., Massaro, J. M., O’Donnell, C. J., Wilson, P. W. F., Vasan, R. S., Sutherland, P. A., Meigs, J. B., Levy, D. A., & D’Agostino, R. B. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.02.002 · Cited by 124
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015) · Hormones · doi:10.1007/bf03401383 · Cited by 117
Thrombin generation in morbid obesity: significant reduction after weight loss
AY, L., KOPP, H. ‐., Brix, J., Ay, C., Quehenberger, P., Schernthaner, G.-H., Pabinger, I., & Schernthaner, G.-H. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03766.x · Cited by 117
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events
Radu, C. M., Spiezia, L., Gavasso, S., Fadin, M., Woodhams, B. J., Vettor, R., Campello, E., Zabeo, E., & Simioni, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0156 · Cited by 110
Vlieg, A. V. H., Baglin, C., Luddington, R. J., MacDonald, S. G., Rosendaal, F. R., & Baglin, T. P. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13043 · Cited by 105
Jensterle, M., Salamun, V., Kocjan, T., Vrtacnik Bokal, E., & Janez, A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0161-3 · Cited by 103
Glintborg, D., Altinok, M. L., Mumm, H., Hermann, A. P., Ravn, P., & Andersen, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1135 · Cited by 88
Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86
Borissoff, J. I., Joosen, I. A., Versteylen, M. O., Spronk, H. M. H., Cate, H. T., & Hofstra, L. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2012.01.023 · Cited by 85
Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep10202 · Cited by 76
Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74
Orio, F., Muscogiuri, G., Giallauria, F., Savastano, S., Bottiglieri, P., Tafuri, D., Predotti, P., Colarieti, G., Colao, A., & Palomba, S. (2016) · Clinical Endocrinology · doi:10.1111/cen.13112 · Cited by 74
Teede, H. J., Meyer, C., Hutchison, S. K., Zoungas, S., McGrath, B. P., & Moran, L. J. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.034 · Cited by 68
Body Composition as Determinant of Thrombin Generation in Plasma
Beijers, H. J. B. H., Ferreira, I., Spronk, H. M. H., Bravenboer, B., Dekker, J. M., Nijpels, G., Cate, H. T., & Stehouwer, C. D. A. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.211946 · Cited by 56
Thomson, R. L., Brinkworth, G. D., Noakes, M., Clifton, P. M., Norman, R. J., & Buckley, J. D. (2012) · Human Reproduction · doi:10.1093/humrep/des138 · Cited by 55
Increased thrombin generation in women with polycystic ovary syndrome
Glintborg, D., Sidelmann, J. J., Altinok, M. L., Mumm, H., & Andersen, M. (2015) · Metabolism · doi:10.1016/j.metabol.2015.06.011 · Cited by 48
Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes
Aziz, M., Sidelmann, J. J., Faber, J., Wissing, M. M., Naver, K. V., Mikkelsen, A., Nilas, L., & Skouby, S. O. (2015) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.12706 · Cited by 40
Self-citationComprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome
Burchall, G., Piva, T. J., Linden, M. D., Gibson‐Helm, M. E., Ranasinha, S., & Teede, H. J. (2015) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1564837 · Cited by 25
Gram, A. S., Bladbjerg, E., Skov, J., Ploug, T., Sjödin, A. M., Rosenkilde, M., Madsen, D. E., & Stallknecht, B. M. (2015) · European Journal of Applied Physiology · doi:10.1007/s00421-015-3106-z · Cited by 24
Fritsch, P. O., Kleber, M., Schlagenhauf, A., Laschnik, B., Fritsch, M., Muntean, W. E., Mangge, H., & Reinehr, T. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.01.042 · Cited by 16
Aziz, M., Sidelmann, J. J., Wissing, M. L., Faber, J. O., & Skouby, S. O. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1032930 · Cited by 14
Self-citationKoiou, E., Τζιόμαλος, Κ., Katsikis, I., Dinas, K. D., Tsourdi, E. A., Kandaraki, E., Delkos, D., Papadakis, E. P., & Panidis, D. (2012) · HORMONES · doi:10.1007/bf03401540 · Cited by 10
Malin Nylander, S. F. (2015) · Journal of Obesity & Weight Loss Therapy · doi:10.4172/2165-7904.1000254 · Cited by 7
Self-citation
Cited by
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics
Glueck, C. J., & Goldenberg, N. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.002 · Cited by 442
Salamun, V., Jensterle, M., Janez, A., & Vrtacnik Bokal, E. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0175 · Cited by 204
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
“The LIPT-study was a double-blind, placebo-controlled RCT.8 In short, inclusion criteria were PCOS (Rotterdam criteria), BMI > 25 kg/m2 and/or presence of IR.”
MethodSelf-citationPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 156
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
“136 137 A meta-analysis of eight randomised controlled trials concluded that GLP-1 agonists were more effective than metformin in improving homeostasis model assessment-insulin resistance (standard mean difference −0.40, 95% confidence interval −0.74 to −0.06), abdominal circumference (−0.45, −0.89…”
Influential
Metadata
- Authors
- Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Nylander, Malin
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2017-02
- Volume
- 6
- Issue
- 2
- Pages
- 89-99
- ISSN
- 2049-3614 (ISSN-L)
- PMC
- PMC5424770
- OpenAlex
- W2580304737
- Cited by
- 44
- References
- 48
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 3
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrine Connections (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gentofte Hospital
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- polycystic ovary syndrome, liraglutide, venous thromboembolism, cardiovascular risk, thrombogenic potential, thrombin generation, plasminogen activator inhibitor-1, fibrinolysis, weight loss, insulin resistance, overweight women, GLP-1 receptor agonists, endogenous thrombin potential, time delay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.